Literature DB >> 28446507

The Microbiota: A New Variable Impacting Cancer Treatment Outcomes.

Jessica L Fessler1, Thomas F Gajewski2,3,4.   

Abstract

Preclinical evidence has established that the host commensal microbiota can contribute to therapeutic response in cancer models, a finding supported by early clinical data. This connection between the microbiome and clinical outcome in oncology is cause for new consideration in the administration of antibiotics and microbiota-modulating interventions to improve outcomes. Clin Cancer Res; 23(13); 3229-31. ©2017 AACRSee related article by Galloway-Peña et al., p. 3263. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28446507      PMCID： PMC5627769          DOI： 10.1158/1078-0432.CCR-17-0864

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Role of the gut microbiota in immunity and inflammatory disease.

Authors:  Nobuhiko Kamada; Sang-Uk Seo; Grace Y Chen; Gabriel Núñez
Journal:  Nat Rev Immunol       Date:  2013-05       Impact factor: 53.106

2.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

3.  Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.

Authors:  Natali Pflug; Sandra Kluth; Jörg J Vehreschild; Jasmin Bahlo; Daniela Tacke; Lena Biehl; Barbara Eichhorst; Kirsten Fischer; Paula Cramer; Anna-Maria Fink; Michael von Bergwelt-Baildon; Stephan Stilgenbauer; Michael Hallek; Oliver A Cornely; Maria J G T Vehreschild
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

Review 4.  Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?

Authors:  Jessica R Galloway-Peña; Robert R Jenq; Samuel A Shelburne
Journal:  Clin Cancer Res       Date:  2017-03-15       Impact factor: 12.531

5.  Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

Authors:  Noriho Iida; Amiran Dzutsev; C Andrew Stewart; Loretta Smith; Nicolas Bouladoux; Rebecca A Weingarten; Daniel A Molina; Rosalba Salcedo; Timothy Back; Sarah Cramer; Ren-Ming Dai; Hiu Kiu; Marco Cardone; Shruti Naik; Anil K Patri; Ena Wang; Francesco M Marincola; Karen M Frank; Yasmine Belkaid; Giorgio Trinchieri; Romina S Goldszmid
Journal:  Science       Date:  2013-11-22       Impact factor: 47.728

6.  The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Authors:  Sophie Viaud; Fabiana Saccheri; Grégoire Mignot; Takahiro Yamazaki; Romain Daillère; Dalil Hannani; David P Enot; Christina Pfirschke; Camilla Engblom; Mikael J Pittet; Andreas Schlitzer; Florent Ginhoux; Lionel Apetoh; Elisabeth Chachaty; Paul-Louis Woerther; Gérard Eberl; Marion Bérard; Chantal Ecobichon; Dominique Clermont; Chantal Bizet; Valérie Gaboriau-Routhiau; Nadine Cerf-Bensussan; Paule Opolon; Nadia Yessaad; Eric Vivier; Bernhard Ryffel; Charles O Elson; Joël Doré; Guido Kroemer; Patricia Lepage; Ivo Gomperts Boneca; François Ghiringhelli; Laurence Zitvogel
Journal:  Science       Date:  2013-11-22       Impact factor: 47.728

7.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Authors:  Ayelet Sivan; Leticia Corrales; Nathaniel Hubert; Jason B Williams; Keston Aquino-Michaels; Zachary M Earley; Franco W Benyamin; Yuk Man Lei; Bana Jabri; Maria-Luisa Alegre; Eugene B Chang; Thomas F Gajewski
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

8.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

Review 9.  Microbiome mediation of infections in the cancer setting.

Authors:  Ying Taur; Eric G Pamer
Journal:  Genome Med       Date:  2016-04-18       Impact factor: 11.117

10.  Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.

Authors:  Krista Dubin; Margaret K Callahan; Boyu Ren; Raya Khanin; Agnes Viale; Lilan Ling; Daniel No; Asia Gobourne; Eric Littmann; Curtis Huttenhower; Eric G Pamer; Jedd D Wolchok
Journal:  Nat Commun       Date:  2016-02-02       Impact factor: 14.919
View more
  8 in total

Review 1.  Temperature as a modulator of the gut microbiome: what are the implications and opportunities for thermal medicine?

Authors:  Bonnie L Hylander; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2019-11       Impact factor: 3.914

2.  T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.

Authors:  Jonathan A Trujillo; Randy F Sweis; Riyue Bao; Jason J Luke
Journal:  Cancer Immunol Res       Date:  2018-09       Impact factor: 11.151

3.  Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer.

Authors:  N Tinsley; C Zhou; S Nahm; S Rack; G C L Tan; P Lorigan; F Blackhall; N Cook
Journal:  ESMO Open       Date:  2022-04-27

Review 4.  Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something.

Authors:  Krishna Kodukula; Douglas V Faller; David N Harpp; Iphigenia Kanara; Julie Pernokas; Mark Pernokas; Whitney R Powers; Nikolaos S Soukos; Kosta Steliou; Walter H Moos
Journal:  Biores Open Access       Date:  2017-10-01

Review 5.  The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.

Authors:  Jun Gong; Alexander Chehrazi-Raffle; Veronica Placencio-Hickok; Michelle Guan; Andrew Hendifar; Ravi Salgia
Journal:  Clin Transl Med       Date:  2019-03-18

6.  The effects of growth hormone on therapy resistance in cancer.

Authors:  Reetobrata Basu; John J Kopchick
Journal:  Cancer Drug Resist       Date:  2019-09-19

7.  Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.

Authors:  Qing Xia; Guojie Chen; Yanbei Ren; Tiansheng Zheng; Changxing Shen; Ming Li; Xiangyun Chen; Hong Zhai; Zhuang Li; Jianfang Xu; Aiqin Gu; Meiling Jin; Lihong Fan
Journal:  BMC Cancer       Date:  2021-06-22       Impact factor: 4.430

8.  Biomineralized Bimetallic Oxide Nanotheranostics for Multimodal Imaging-Guided Combination Therapy.

Authors:  Jianrong Wu; Gareth R Williams; Shiwei Niu; Yanbo Yang; Yu Li; Xuejing Zhang; Li-Min Zhu
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.